Date: 2015-08-10
Type of information: Milestone
Compound: small molecule-based immuno-oncology therapies
Company: Apeiron Biologics (Austria) Evotec (Germany) Sanofi (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D - research - development - licensing
Action mechanism:
Disease: hematological cancers, solid tumors
Details:
- • On August 10, 2015, Sanofi announced that it has entered a research collaboration and license agreement with Evotec and Apeiron Biologics to discover and develop first-in-class small molecule-based immuno-oncology therapies to treat solid and hematological cancers by enhancing the anti-tumor activity of the human immune system. Based on Evotec\'s technological expertise and Apeiron Biologics\' experience with immunology, the new collaboration will focus on the identification of novel small molecules and their targets to develop next-generation therapies in immuno-oncology. These treatments are expected to complement currently available checkpoint inhibitors. The collaboration is based on the initial successful outcome of a phenotypic high throughput screen of potential compounds for development that was commissioned by Apeiron Biologics and conducted by Evotec. Under the collaboration, Sanofi has the option of screening its own compound libraries to identify new small molecule candidates for development. Under the terms of the agreement, Sanofi will have sole responsibility for all development, regulatory, commercial and manufacturing activities of the products resulting from the collaboration.
Financial terms:
- Sanofi will support two years of funding for Evotec and Apeiron to conduct the research program, which will include potential early success milestone payments. Upon continuation, as decided by Sanofi, Evotec will be entitled to receive further development, regulatory and commercial milestone payments, which could total more than €200 million, and royalties on net sales.
Latest news:
- • On January 8, 2018, Apeiron Biologics and Evotec announced that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of € 3 million will be split equally between the two biotech companies. The success payment was triggered when the partners successfully advanced an undisclosed, novel, immuno-oncology small molecule into late-stage pre-clinical development. Under the alliance, the three companies work together to identify small molecule leads and targets for next-generation therapies in immuno-oncology, which may complement the pre-clinical and clinical profiles of leading checkpoint inhibitors.
Is general: Yes
